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ABSTRACT  28 
Background: Discrimination promotes multi-system physiological dysregulation termed 29 
allostatic load, which predicts morbidity and mortality.  It remains unclear whether weight-30 
related discrimination influences allostatic load.   31 
Purpose: To prospectively examine 10-year associations between weight discrimination, 32 
allostatic load, and its components among adults 25-75y in the Midlife Development in the US 33 
Biomarker Substudy. 34 
Methods: Participants with information on weight discrimination were analyzed (n=986). At 35 
both timepoints, participants self-reported the frequency of perceived weight discrimination 36 
across nine scenarios as ‘never/rarely’ (scored as 0), ‘sometimes’ (1), or ‘often’ (2). The two 37 
scores were averaged and then dichotomized as ‘experienced’ versus ‘not experienced’ 38 
discrimination. High allostatic load was defined as having ≥3 out of 7 dysregulated systems 39 
(cardiovascular, sympathetic/parasympathetic nervous systems, hypothalamic pituitary axis, 40 
inflammatory, lipid/metabolic, and glucose metabolism), which collectively included 24 41 
biomarkers. Relative risks (RR) were estimated from multivariate models adjusted for socio-42 
demographic and health characteristics, other forms of discrimination, and BMI. 43 
Results: Over 41% of the sample had obesity, and 6% reported weight discrimination at follow-44 
up. In multivariable-adjusted analyses, individuals who experienced (versus did not experience) 45 
weight discrimination had twice the risk of high allostatic load (RR: 2.07, 95%CI: 1.21, 3.55 for 46 
baseline discrimination; 2.16, 95%CI: 1.39, 3.36 for long-term discrimination). Weight 47 
discrimination was associated with lipid/metabolic dysregulation (1.56, 95%CI: 1.02, 2.40), 48 
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glucose metabolism (1.99, 95% CI: 1.34, 2.95), and inflammation (1.76, 95% CI: 1.22, 2.54), but 49 
no other systems. 50 
Conclusions: Perceived weight discrimination doubles the 10-year risk of high allostatic load. 51 
Eliminating weight stigma may reduce physiological dysregulation, improving obesity-related 52 
morbidity and mortality. 53 
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INTRODUCTION  60 
Obesity is the leading contributor to disability-adjusted life-years in the US, at least partly 61 
due to its adverse effects on multiple health outcomes (1). It is well-established that obesity 62 
etiology is both complex and manifold (2), suggesting a need for integrated biopsychosocial and 63 
biomedical approaches to address it (3).  Despite this, predominant approaches to treat obesity 64 
continue to accentuate the role of the individual (4), unintentionally contributing to a cycle that 65 
further entrenches obesity and its related health consequences by promoting stigmatization of 66 
this condition (3, 4).  67 
Research suggests that pervasive individually-targeted health campaigns increase public 68 
prejudice toward individuals with obesity by increasing the perception of obesity as a lifestyle 69 
choice resulting from weakness of character (5).  A downward consequence of this perception is 70 
increased weight-related stigma, and often, discrimination (6, 7). Weight discrimination is the 71 
fourth most prevalent form of discrimination among adults, after age, sex, and race-based 72 
discrimination (8).  Between 1995 and 2006, the absolute prevalence of weight discrimination 73 
increased from 7% to 12% in the US, representing a 66% increase in prevalence and exceeding 74 
the proportion that could be attributed to concomitant increases in obesity (9).  Despite the lay 75 
belief that weight stigma motivates positive behavioral change (10), most evidence demonstrates 76 
that weight shaming promotes poorer dietary and exercise practices and health care avoidance 77 
(11, 12), akin to how experienced racism correlates with negative health outcomes like cancer 78 
risk (13, 14).  As such, weight discrimination may contribute to obesity (3, 15) by discouraging 79 
individuals from seeking treatment, reducing engagement with social support, or promoting 80 
disordered eating patterns, less healthful food choices, and emotional dysregulation (12, 16-21).  81 
Furthermore, weight stigma has been directly linked to overeating and physical inactivity in 82 
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randomized controlled trials (10), providing plausible mechanisms through which weight stigma 83 
promotes physiologic dysregulation. 84 
Discrimination also affects chronic stress, which could subsequently promote adverse 85 
physiologic changes (3, 15, 22-24).  For example, weight stigma has been associated with higher 86 
glycemic parameters (24) and C-reactive protein (CRP) (15) in large, longitudinal studies.  In 87 
studies where weight stigma was experimentally manipulated, greater stigmatization resulted in 88 
sustained cortisol secretion (22, 25). These findings echo existing research on the effects of 89 
perceived discrimination on allostatic load (26, 27), suggesting that there may be a similar 90 
connection between weight discrimination and physiologic dysregulation.  91 
Allostatic load refers to the cumulative adverse adaptation of multiple physiological 92 
systems (i.e. cardiovascular, sympathetic, parasympathetic, metabolic, etc.) in response to 93 
chronic stressors, which has been more strongly associated with chronic disease morbidity and 94 
mortality than traditional risk markers (28, 29).  Although the operational definitions of allostatic 95 
load vary across studies (28), the allostatic load metric is considered a robust estimator of multi-96 
system dysregulation in population studies (30). While it is valuable to examine allostatic load as 97 
a composite score, examining dysregulation within the individual allostatic load systems can 98 
help identify underlying pathways through which the allostatic load response is manifested, 99 
according to the population’s specific characteristics (30). As such, we examined whether the 100 
chronic stress associated with weight discrimination impacts both allostatic load and seven 101 
individual systems used to define allostatic load to elucidate the underlying pathways through 102 
which weight discrimination promotes dysregulation. 103 
We propose that weight-related discrimination triggers multi-system dysregulation that 104 
adversely affects other health outcomes (e.g. cardiovascular disease) beyond the effects of 105 
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obesity alone (Figure 1).  Similar to the cyclic obesity/weight-based stigma (COBWEBS) model 106 
(3), weight-related discrimination is characterized as a stressor that triggers a downward cascade 107 
of unfavorable psychosocial and behavioral processes that ultimately result in poor biological 108 
outcomes across multiple systems (e.g. metabolic syndrome, cardiovascular disease) (31, 32). To 109 
test this hypothesis, we used unique data from the national survey of Midlife Development in the 110 
US (MIDUS) study to prospectively examine the 10-year associations between perceived weight 111 
discrimination and allostatic load among adults ages 25-74y. 112 
 113 
METHODS 114 
Participants 115 
We used data from the MIDUS I (1995-1996), MIDUS II (2004-2006), and MIDUS 116 
Biomarker Substudy (2004-2009) to examine associations between perceived weight 117 
discrimination, allostatic load, and the individual systems comprising allostatic load.  Detailed 118 
information about the study’s sampling procedures have been previously published (33).  Briefly, 119 
7,108 non-institutionalized adults (including 950 siblings and 1,914 twins) aged 25-74y 120 
participated in a telephone survey conducted via random digit dialing in 1995-1996.  At follow-121 
up between 9 and 10 years later, approximately 4,900 members of the original cohort responded 122 
to an additional phone survey; the mortality-adjusted longitudinal response rate at MIDUS II was 123 
75%.  During the 10-year follow-up, a subset of 1,255 adults who completed the phone interview 124 
and questionnaires were randomly selected and invited to participate in a biomarker substudy. 125 
The present analysis includes those in the biomarker sub-study with sufficient information to 126 
compute allostatic load (n=1,233) or the individual allostatic load systems (n=1,158-1,254) and 127 
who had information on perceived weight discrimination (n=986). 128 
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Perceived Weight Discrimination 129 
 Participants self-reported instances of perceived discrimination within interpersonal 130 
relationships on a day-to-day basis at both the baseline and 10-year follow-up survey.  Nine 131 
scenarios about interpersonal discrimination were queried with the question ‘How often on a 132 
day-to-day basis do you experience each of the following types of discrimination?’  The 133 
scenarios included: ‘you are treated with less courtesy than other people’, ‘you are treated with 134 
less respect than other people’, ‘you receive poorer service than other people at restaurants or 135 
stores’, ‘people act as if they are afraid of you’, ‘people act as if they think you are dishonest’, 136 
‘people act as if they think you are not as good as they are’, ‘you are called names or insulted’, 137 
and ‘you are threatened or harassed’.  The frequency categories for these scenarios included 138 
‘Often’, ‘Sometimes’, ‘Rarely’, or ‘Never’.  These questions were initially developed for a study 139 
examining racial discrimination, and have been used widely since then (34).  140 
 Similar to Puhl and others (8), only participants reporting discrimination ‘Sometimes’ or 141 
‘Often’ were counted as instances of discrimination.  We constructed a continuous measure of 142 
perceived discrimination that allocated 2 points for every instance that a discrimination scenario 143 
was reported as ‘Often’, 1 point for every scenario reported as ‘Sometimes’, and 0 points for 144 
those who reported discrimination ‘Rarely’ or ‘Never’.  Separately, participants were asked to 145 
select the primary reason(s) for discrimination, from among the following options: age, gender, 146 
race, height or weight, ethnicity or nationality, physical disability, some aspect of appearance 147 
other than weight or height, sexual orientation, religion, and other reason.  Like previous studies, 148 
we refer to the ‘height or weight’ variable as ‘weight discrimination’ throughout the manuscript 149 
(8).   150 
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We constructed two variables for perceived weight discrimination at both baseline and 151 
10-year follow-up.  First, a continuous measure of perceived weight discrimination was 152 
computed from the continuous perceived discrimination score for individuals who reported 153 
‘weight’ as a primary reason for discrimination.  The observed range for this score was 0-10 at 154 
baseline and 10-year follow-up.  Secondly, a categorical indicator variable was created for 155 
individuals who experienced any vs. no perceived weight discrimination. 156 
Individuals who reported no instances of discrimination received a weight discrimination 157 
score of 0 (n=126). We also carried baseline values forward for non-responders at the 10-year 158 
follow-up who reported discrimination related to weight at baseline based on the correlation 159 
between these two measures (n=215, r=0.40, p<0.0001).  Individuals who refused to respond to 160 
the question or whose responses were deemed ‘inappropriate’ by study administrators were 161 
coded as missing (n=46). Complete information was available for 986 participants at baseline 162 
and 940 at follow-up.  The two exposures of interest were baseline weight discrimination and 163 
long-term weight discrimination.  Long-term discrimination was computed as the average value 164 
of perceived discrimination at baseline and at 10-year follow-up or as discrimination at 10-years 165 
for individuals with missing baseline data.  166 
Allostatic Load 167 
  Allostatic load was comprehensively measured and defined in accordance with previous 168 
studies conducted within this population using a score that captured dysregulation across seven 169 
systems, including the sympathetic and parasympathetic nervous systems, hypothalamic pituitary 170 
adrenal (HPA) axis, cardiovascular functioning, lipid and general metabolic activity, glucose 171 
metabolism, and inflammatory system(31, 35, 36) (Table 1).  All physiologic measures were 172 
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collected during the Biomarker Substudy visit, which corresponded with the timing of the 10-173 
year follow-up exam.  174 
Sympathetic nervous system functioning was measured with 12-hour overnight urinary 175 
measurements of epinephrine and norepinephrine via high-pressure liquid chromatography, and 176 
levels were reported per level of creatinine (g).  Parasympathetic nervous system activity was 177 
measured by four heart rate variability parameters during an 11-minute seated rest period using 178 
an electrocardiograph: low frequency spectral power, high frequency spectral power, the 179 
standard deviation of heartbeat to heartbeat intervals, and the root mean square of successive 180 
differences.  Overnight urinary cortisol and serum dehydroepiandrosterone sulfate (DHEA-S) 181 
were used as markers of HPA activity.  Markers of cardiovascular functioning included resting 182 
systolic blood pressure (SBP), heart rate, and pulse pressure.  Lipid/fat metabolism markers 183 
included high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, body 184 
mass index (BMI), and waist-to-hip ratio (WHR).  Glycosylated hemoglobin (HbA1c), fasting 185 
glucose, and the homeostasis model of insulin resistance (HOMA-IR) were used to assess 186 
glucose metabolism.  Inflammation was measured with plasma CRP, fibrinogen, serum 187 
interleukin-6 (IL6), the soluble adhesion molecule E-selectin, and intracellular adhesion 188 
molecule-1. All blood, urine, saliva, cardiovascular, and heart rate variability measurements were 189 
collected during an overnight stay at one of three University General Clinical Research Centers. 190 
Detailed collection protocols for each biomarker have been previously published (31, 37).  191 
Consistent with previous studies (36), we computed a system risk score for each of the seven 192 
systems that was in the upper or lower quartile of the biomarker population-specific distribution, 193 
based on whether high or low values of the parameter were generally associated with higher 194 
health risk.  Additionally, consistent with previous research (35, 38-40), participants who 195 
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reported using medications to treat dysregulated parameters were categorized as high risk for that 196 
parameter to account for pre-existing dysregulation.  These medications included 197 
antihypertensive medications for high SBP; heart rate-reducing medications (e.g. beta-blockers 198 
and atrio-ventricular nodal blockers) for high resting heart rate; hypoglycemic agents for 199 
dysregulated fasting glucose and HbA1c; statins, cholesterol absorption inhibitors, niacin and/or 200 
bile acid sequestrants for dysregulated LDL; fibrates for elevated serum triglycerides; 201 
testosterone for dysregulated DHEA-S, and anti-inflammatory medications (including non-202 
steroidal anti-inflammatory medications) for dysregulated CRP and IL-6. The number of 203 
participants with dysregulated parameters including and excluding medication data in the 204 
definition of allostatic load is shown on Supplemental Table 1.  In sensitivity analyses, we 205 
examined all associations excluding the use of medications in the definitions of system 206 
dysregulation.  207 
System risk scores were continuous and computed by calculating the proportion of 208 
individual biomarkers within the system that were dysregulated.  Scores could range from 0 to 1 209 
(corresponding with 0-100% of system biomarkers in high-risk range).  We only computed 210 
system risk scores for participants with values for at least half of the system’s biomarkers.  Over 211 
90% of participants had information for all 7 systems, and most participants (98%) had complete 212 
data for all systems excluding the parasympathetic measures; 106 participants (8%) were missing 213 
information on the parasympathetic parameters due to instrumentation failures and/or 214 
measurement difficulties.  215 
The allostatic load variable was computed for participants with data on at least six of the 216 
seven systems by summing the seven system risk scores; total allostatic load scores ranged from 217 
0 to 7, with higher scores indicative of more dysregulation.  An indicator variable for high versus 218 
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low allostatic load was created: allostatic load summary scores ≥3 were considered “high” and 219 
scores <3 were considered “low.” Although the median allostatic load score in this population 220 
was 2, using a higher cut-point allowed us to capture individuals at higher disease risk (39). 221 
Covariates 222 
Potential confounding variables were selected based on their relevance from prior 223 
literature.  We used self-reported information collected during the follow-up period for these 224 
variables: age, race (white, black, other), household income (>$100,000/year), educational 225 
attainment (< high school, high school graduate, some college, college graduate or more), 226 
smoking status (never, former, current) and physical activity (engagement in regular exercise at 227 
least 20 minutes 3 times per week).  Baseline rather than follow-up values were used for BMI 228 
and for perceived discrimination related to age, race, and/or sex (the three most common forms 229 
of discrimination (8)) because prolonged stress is more strongly related to allostatic load (28).  230 
These variables were computed in the same manner as weight discrimination.  231 
Statistical Methods 232 
Mixed linear models with maximum likelihood estimation and family membership as a 233 
random effect were used to examine the continuous associations between perceived weight 234 
discrimination and allostatic load. Family membership was incorporated as a random effect to 235 
account for clustering since the sample included participants from the sibling/twin subsamples of 236 
the main MIDUS study (31).  A generalized linear model procedure was used to estimate relative 237 
risks (RR) using Poisson regression with robust error variance (41), as this method produces 238 
95% confidence intervals with the correct coverage.  Base models were adjusted for age and sex. 239 
The first multivariable adjusted model (Model 1) further adjusted for race, household income, 240 
smoking status, and educational attainment.  Model 2 further incorporated physical activity, and 241 
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Model 3 was further adjusted for baseline perceived race, sex, and age discrimination.  Our final 242 
model (Model 4) also adjusted for baseline BMI. We tested for the presence of interactions 243 
between perceived weight discrimination and sex, BMI, physical activity, smoking status, and 244 
race, sex, or age discrimination using a p-value<0.05 to establish significance.  We also used 245 
Baron and Kenny criteria (42) to examine whether health behaviors like smoking and physical 246 
activity mediated the association between weight discrimination and allostatic load.  247 
Additionally, we examined the associations between perceived weight discrimination and 248 
individual system dysregulation in order to provide insight into the biological pathways 249 
underlying any observed associations.  Finally, in sensitivity analyses, we excluded BMI and 250 
WHR from the definition of lipid/metabolic dysregulation in the calculation of allostatic load.  251 
All analyses were conducted with SAS v 9.4 (SAS Institute Inc., Cary, NC, USA). 252 
 253 
RESULTS 254 
The study sample was predominately comprised of white (93%), female (57%), middle-255 
aged adults (mean age=57y) with high educational attainment (47% with a college education or 256 
higher) (Table 2).  More than 75% of participants reported engaging in regular physical activity, 257 
15% were current smokers, and more than 75% were classified with either overweight or obesity.  258 
At baseline, nearly 4% of participants reported experiencing weight-related discrimination, with 259 
an average discrimination score of 0.13 (0.76).  At follow-up, this percentage increased to 260 
approximately 6% with average discrimination values of 0.22 (1.09).  When medication was 261 
included in the definition of high allostatic load, 18% of participants met the criteria, while only 262 
13% met the criteria when medication usage was excluded.   263 
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No significant interactions between perceived weight discrimination and relevant 264 
covariates were detected (data not shown).  Results were similar regardless of whether we used 265 
medications to operationalize allostatic load; thus, those presented hereafter include medication 266 
information to capture already-deregulated parameters.  Compared to individuals who did not 267 
experience weight discrimination, both baseline and long-term perceived weight discrimination 268 
were associated with more than double the risk of high allostatic load in final multivariable 269 
models (RR: 2.07, 95%CI: 1.21, 3.55 for baseline discrimination and RR: 2.16, 95%CI: 1.39, 270 
3.36 for long-term discrimination) (Table 3).  Similar associations were observed when these 271 
associations were examined using the continuous weight discrimination score and allostatic load 272 
variables (β=0.11, p=0.01 for baseline discrimination and β=0. 19, p=0.0001 for long-term 273 
discrimination).  Additionally, the effect of weight discrimination on allostatic load was partly 274 
mediated (~5%) through decreased physical activity among those who experienced versus did 275 
not experience weight discrimination (data not shown). Perceived race, sex, and age 276 
discrimination were not significantly associated with allostatic load in final models (data not 277 
shown).  In sensitivity analyses, when BMI and WHR were excluded from the definition of 278 
allostatic load, baseline perceived weight discrimination was not significantly associated with 279 
allostatic load, but long-term weight discrimination remained associated with allostatic load after 280 
controlling for baseline BMI (RR:1.62, 95%CI: 1.01, 2.62; p=0.047). 281 
Overall, compared to individuals reporting no weight-related discrimination, long-term 282 
weight discrimination was most strongly associated with metabolic/lipid dysregulation (RR: 283 
1.56, 95%CI: 1.02, 2.40), glucose metabolism (RR:1.99, 95% CI: 1.34, 2.95), and inflammatory 284 
parameters (RR: 1.76. 95% CI: 1.22, 2.54) after adjustment for other confounding variables 285 
including baseline BMI (Table 4). Weight discrimination was not significantly associated with 286 
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CVD function, sympathetic or parasympathetic nervous system dysregulation, or HPA 287 
dysfunction. 288 
 289 
DISCUSSION 290 
 Perceived baseline and long-term weight discrimination were associated with more than 291 
twice the risk of high allostatic load in this sample.  The detrimental effects of weight 292 
discrimination on allostatic load persisted following adjustment for BMI, suggesting that 293 
perceived weight-related discrimination adversely affects overall physiological regulation 294 
beyond what can be attributed to excess weight alone.  Further support for the independent 295 
associations between weight discrimination and allostatic load were observed when BMI and 296 
WHR were excluded from the operationalization of allostatic load, and the long-term 297 
associations remained significant. When the individual systems comprising allostatic load were 298 
examined separately, perceived weight discrimination was most strongly associated with 299 
lipid/metabolic dysregulation, glucose metabolism, and markers of inflammation.  Taken 300 
together, these results suggest that the stigma associated with having excess weight adversely 301 
influences allostatic load, and potentially chronic disease morbidity and mortality, highlighting a 302 
need for prevention efforts to reduce weight-related stigma in diverse settings.  303 
While limited, empirical studies demonstrate that reducing weight-related stigma 304 
favorably affects weight-loss self-efficacy and attitudes toward exercise.  In an experimental 305 
study, Pearl and Lebowitz (2014) demonstrated that overweight and obese participants who read 306 
passages that implicate the food environment vs. personal responsibility in obesity etiology had 307 
greater self-efficacy to lose weight and no increase in weight stigmatizing attitudes that 308 
adversely affect weight control (5).  Similarly, US women exposed to neutral vs. stereotypical 309 
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images of a woman with obesity exercising had more favorable attitudes toward exercise 310 
engagement and lower weight-based stigma (43). 311 
Our results suggest that perceiving weight discrimination can adversely affect multiple 312 
biological systems and are consistent with research examining individual biomarkers.  In 313 
MIDUS, Tsenkova and others (24) noted that experiencing weight discrimination amplified the 314 
adverse effects of elevated WHR on HbA1c.  Among community-dwelling adults with diabetes, 315 
researchers found that participants experienced worse glycemic outcomes if they had 316 
experienced weight-based discrimination (11).  Similar to the present study, the changes in 317 
glycemic markers persisted even after accounting for body weight and other forms of 318 
discrimination (11).  Moreover, the participants from the study conducted by Potter and others 319 
also reported worse diabetes self-care practices related to diet, exercise, and blood glucose 320 
monitoring, providing insight into the pathways by which weight discrimination adversely 321 
impacts physiologic parameters.  These observed negative behavioral adaptations support the 322 
pathways proposed in our conceptual model relating weight discrimination to allostatic load. 323 
Another study noted that weight-related discrimination was associated with inflammatory 324 
markers like CRP among overweight but not obese individuals (15), and also suggested that 325 
worse self-care practices may underlie the associations between weight-related discrimination 326 
and health outcomes.  The significant findings in overweight rather than obese individuals 327 
implied that that weight discrimination may support the development and maintenance of obesity 328 
by activating inflammatory pathways (15).  329 
Although allostatic load should primarily be evaluated as a matrix of dysregulated 330 
systems, investigating the individual systems informs our understanding of the biological 331 
underpinnings of an important risk marker.  This study primarily implicated 3 of the 7 systems in 332 
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the association between weight discrimination and allostatic load, potentially identifying relevant 333 
treatment priorities.  However, additional research into all systems remains necessary because 334 
the time course of metabolic dysregulation and the duration and mechanism of action of the 335 
biomarkers is not well understood.  For example, it remains unclear whether obesity precedes 336 
HPA axis dysregulation or vice versa, and whether it results in hypo- or hyperactivity or 337 
volatility (44).  In the present study, many of the primary markers of HPA axis and CVD 338 
dysregulation associated with allostatic load were not affected by perceived weight 339 
discrimination, potentially suggesting that obesity precedes HPA axis dysregulation and induces 340 
some volatility (44).  However, because adrenal cortisol and adipose tissue cortisol may be 341 
differentially affected by obesity (44) and because biomarkers were only measured once during 342 
the follow-up period, we may have been unable to discern the critical window and/or site where 343 
HPA dysregulation would occur.   344 
Experiencing weight discrimination appears to promote many of the pathologic features 345 
of obesity, such as inflammation, lipid/metabolic imbalances, glycemic dysregulation, and more 346 
holistically, allostatic load.  Although the pathways through which weight discrimination 347 
influences allostatic load may be interconnected and multifactorial, this complexity provides 348 
promising opportunities for further research.  It may be informative to investigate how 349 
discrimination relates to allostatic load parameters in more diverse populations where being 350 
overweight is less stigmatized, and whether factors like healthcare access can also modulate the 351 
effect of weight discrimination on health.  While we did not detect any significant interactions 352 
between perceived weight discrimination and physical activity or smoking, and detected minimal 353 
mediation through physical activity, other research has found that health behaviors during 354 
adulthood partly explain the association between adverse events in early life and subsequent 355 
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allostatic load (45).  For example, research in MIDUS has established a link between positive 356 
coping strategies and social support on allostatic load (36) that warrants additional exploration in 357 
individuals who experience weight discrimination.  Physical activity also deserves further 358 
attention as it is possible that a more precise measure would more strongly mediate the 359 
association between weight discrimination and allostatic load.  360 
In addition, while the associations between weight discrimination and allostatic load were 361 
robust in this study, 10-years of follow-up may provide only an indication of the potential full 362 
effect that weight discrimination could have on cumulative physiological dysregulation 363 
throughout longer periods of time or at different lifecycles.  More longitudinal research with 364 
longer follow-up periods and repeated measurements would enhance our understanding of the 365 
time course of weight discrimination related to allostatic load development as well as critical 366 
windows when risk can be modified (28).  Finally, it may be important to establish confluence 367 
between clinical-cut points and population-based cut-points for the various biomarkers 368 
encompassing allostatic load to more accurately determine risk estimates.  369 
Some limitations of the present analysis must be noted.  Dietary information was not 370 
collected in the MIDUS study, which may be an important confounding or mediating variable in 371 
the association between perceived weight discrimination and allostatic load – particularly 372 
because poor dietary choices have been related to the effects of discrimination on glycemic 373 
control (46).  Participant non-response rates on the questions about perceived discrimination also 374 
reduced the final sample size.  Because non-response was higher among smoking, younger, 375 
women with lower self-reported physical activity, and higher BMI at baseline (data not shown), 376 
we expect that our risk estimates were attenuated and that the associations between weight 377 
discrimination and allostatic load are actually stronger than what we were able to observe.  378 
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Finally, because participants could select multiple primary reasons for discrimination, it is 379 
possible that individuals who reported multiple forms of discrimination differed from individuals 380 
who only reported weight discrimination.  However, associations did not change after controlling 381 
for other forms of reported discrimination, which improves the robustness of our findings.  382 
The present study has several strengths that warrant mention.  First, this study utilizes 383 
data from a large US national sample.  Additionally, much research to date examining allostatic 384 
load have used limited markers or have been cross-sectional despite a call for more longitudinal 385 
research (28); our study precisely measured multiple biomarkers across 7 systems, and the nearly 386 
10 years of follow-up provide important insight into the cumulative effects of weight 387 
discrimination as a stressor on multi-system dysregulation.  By accounting for family 388 
relationships within the cohort, we reduced bias related to shared genetic or environmental 389 
factors that contribute to weight and metabolic dysregulation. The present study also builds upon 390 
existing evidence that self-reported weight discrimination adversely influences biochemical 391 
parameters beyond the effect of actual weight (11).  Given the established connection between 392 
personal responsibility campaigns and increased obesity stigma (5), the results from this study 393 
have important policy implications with respect to framing obesity prevention campaigns as well 394 
as treatment implications for clinicians working with clients with obesity. 395 
The adverse health effects of obesity are well documented and require concerted efforts 396 
to treat.  The emphasis on personal responsibility in the US has had the effect of further 397 
stigmatizing obesity, resulting in less favorable health outcomes within this vulnerable 398 
population (4).  Weight discrimination was recently associated with a nearly 60% increase in 399 
overall mortality risk among MIDUS participants (47), and it is plausible that this hazard is at 400 
least partly mediated by allostatic load. The magnitude of risk observed between weight 401 
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discrimination and allostatic load is greater than what has been observed for poor quality dietary 402 
patterns and allostatic load (40), and comparable to physical inactivity (48), drawing attention to 403 
weight discrimination as a significant allostatic load risk factor.  Given that high allostatic load 404 
has been shown to be robustly associated with type 2 diabetes, hypertension, cardiovascular 405 
disease, and mortality (39, 49), targeted efforts to reduce weight discrimination are warranted.  406 
From a disease prevention standpoint, it is imperative to develop less stigmatizing public health 407 
campaigns and clinical approaches to reduce physiological dysregulation and long-term chronic 408 
disease risk among individuals with obesity or at risk for obesity.  Simultaneously, directed 409 
efforts to better understand the pathways through which weight discrimination influences 410 
allostatic load can improve treatment targets and health outcomes among the substantial 411 
proportion of the population with weight-related comorbidities. 412 
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Figure 1: Conceptual model of potential pathways through which obesity and weight discrimination are associated with allostatic load 591 
(Adapted from Gruenwald et al, 2012(31) and Tomiyama et al. 2014(3)  592 
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Table 1: Mean values and population-specific high-risk cutpoints for allostatic load parameters in 594 
the MIDUS Biomarker Substudy  595 
System and Representative 
Biomarkers 
N Mean SD Min Max High-risk cutpoint by 
population-specific 
quartile 
Cardiovascular       
Resting SBP (mmHg) 1254 131.5 18.3 83.0 222.0 ≥144.0 (n=309) 
Resting heart rate (bpm) 1253 71.1 11.2 36.0 111.0 ≥79.0 (n=314) 
Resting pulse pressure 
(mmHg) 
1254 55.8 14.7 24.0 114.0 ≥65.0 (n=312)  
 
Metabolic- lipids       
BMI (kg/m2) 1254 29.8 6.63 15.0 65.1 ≥33.1 (n=313) 
WHR 1253 0.89 0.10 0.62 1.72 ≥0.97 (n=316) 
Triglycerides (mg/dL) 1244 132.5 131.8 25.0 3299.0 ≥156.0 (n=312) 
HDL Cholesterol (mg/dL) 1242 55.4 18.0 19.0 121.0 ≤42.0 
(n=310) 
LDL Cholesterol (mg/dL) 1242 105.5 35.4 6.00 283.0 ≥128.0 (n=310) 
Metabolic- glucose 
metabolism 
      
Glycosylated hemoglobin (%) 1235 6.10 1.16 3.58 19.7 ≥6.24 (n=314) 
Fasting glucose (mg/dL) 1236 102.1 28.4 5.00 418.0 ≥105.0 (n=314) 
Insulin resistance (HOMA-
IR) 
1236 3.58 3.98 0.04 53.7 ≥4.36 (n=310) 
Inflammation       
CRP (mg/L) 1235 3.02 4.78 0.14 61.7 ≥3.66 (n=309) 
IL6 (pg/mL) 1243 3.04 3.04 0.16 23.0 ≥3.48 (n=310) 
Fibrinogen (mg/dL) 1235 348.9 87.8 45.0 857.0 ≥399.0 (n=313) 
sE-Selectin (ng/MI) 1242 43.4 22.7 0.09 178.1 ≥51.9 (n=310) 
sICAM-1 (ng/MI) 1242 288.5 115.6 44.0 1076.6 ≥335.8 (n=310) 
Sympathetic Nervous System       
Urine Epinephrine (ug/g 
creatine) 
1233 1.96 1.28 0.09 10.6 ≥2.47 (n=308) 
Urine Norepinephrine (ug/g 
creatine) 
1243 27.4 13.9 3.50 187.1 ≥33.0 (n=311) 
Hypothalamic Pituitary 
Adrenal Axis 
      
Urine Cortisol (ug/g creatine) 1252 15.8 24.6 0.40 725.0 ≥20.0 (n=308) 
Blood DHEA-S (ug/dL) 1239 105.1 77.0 0.90 685.0 ≤51.0 (n=313) 
Parasympathetic Nervous 
System 
      
SDRR (msec) 1148 35.6 17.2 5.56 138.8 ≤23.7 (n=287) 
26 
 
RMSSD 1148 22.9 17.7 2.64 209.7 ≤12.1 (n=287) 
Low frequency spectral 
power 
1148 424.3 607.5 1.60 10943.6 ≤114.6 (n=287) 
High frequency spectral 
power 
1148 316.5 729.4 2.45 15731.7 ≤58.8 (n=287) 
Allostatic Load 1233 1.72 1.03 0 5.03  
Allostatic Load (with 
medication data) 
1233 1.94 1.10 0 5.37  
Abbreviations: BMI: body mass index; CRP: C-reactive protein; DHEA-S: dehydroepiandrosterone sulfate; 596 
PNS: parasympathetic nervous system; HPA: hypothalamic pituitary axis; IL6: interleukin-6; RMSSD: root 597 
mean square of successive differences; SBP: systolic blood pressure, SDRR: the standard deviation of R-R 598 
(heartbeat to heartbeat) intervals; sE-selectin: soluble adhesion molecule E-selectin; sICAM: soluble 599 
intracellular adhesion molecule-1; SNS: sympathetic nervous system 600 
Allostatic Load was defined in accordance with previous studies conducted within this population using a score 601 
that captured dysregulation across seven systems, including multiple markers of cardiovascular pathways, 602 
Sympathetic Nervous System, Parasympathetic Nervous System, HPA axis, inflammation, lipid and general 603 
metabolic activity, and glucose metabolism, and could range from 0 to 7.  604 
 605 
  606 
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Table 2: Descriptive characteristics of the MIDUS participants at 10-year follow-up, (n=932-1,255)a 607 
Age 57.3 (11.5) 
Sex (% female) 56.8 
Race  
White 93.1 
Black 2.6 
Other 4.4 
Educational attainment (%)   
Less than high school 4.3 
High school  19.9 
Some college 29.2 
College and above 46.6 
Household income (>$100,000/year) 21.4 
Regular physical activity (%)b 76.5 
Smoking status (%)  
Never 52.4 
Past 32.6 
Current 14.9 
Body Mass Index 29.8 (6.6) 
Weight category (%)  
Overweight 35.1 
Obesity 41.2 
Perceived weight discrimination (%) c  
Baseline 3.96 
10-year follow-up 6.17 
Perceived weight discrimination score c  
Baseline 0.13 (0.76) 
10-year follow-up 0.22 (1.09) 
High allostatic loadd 18.3 
High allostatic load (excluding medication)d 12.9 
aContinuous variables are expressed as mean (SD) and categorical variables as percentages 608 
bPhysical activity was defined as the percentage who regularly exercised at least 20 min 3 times per week.   609 
cPerceived weight discrimination measured how often participants experienced discrimination due to their weight in 610 
nine situations on a daily basis.  For the categorical measure, anyone who reported any weight discrimination 611 
(“often” or “sometimes”) was counted.  For the continuous score measure, we summed the number of instances a 612 
person reported discrimination “sometimes” (assigned as 1 point) or “often” (assigned as 2 points).  Individuals who 613 
reported discrimination “never” or “rarely” received a score of 0.  Baseline values were carried forward for 614 
individuals who reported weight discrimination at baseline, but had missing data at follow-up. 615 
dHigh allostatic load was defined as greater than or equal to 3 dysregulated systems and low allostatic load was 616 
defined as less than 3.  Allostatic load was measured at follow-up. 617 
 618 
619 
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Table 3: Relative Risk of High Allostatic Load based on Perceived Baseline and Long-Term Weight Discrimination 620 
in the MIDUS Study 621 
 High Allostatic Loada Continuous Allostatic 
Loadb 
High Allostatic Load  
(excluding BMI and 
WHR) 
 RR 95% CI p-value β SE p-value RR 95% CI p-
value 
Baseline perceived 
weight discriminationc 
         
Age- and sex-adjusted 
 
2.60 1.60, 4.23 0.0001 0.15  0.04 0.0005 1.92 1.14, 3.23 0.01 
Multivariable-adjusted 
Model 1d 
 
2.42 1.44, 4.04 0.0008 0.14 0.04 0.001 1.78 1.02, 3.11 0.04 
Multivariable-adjusted 
Model 2e 
 
2.31 1.38, 3.84 0.001 0.13 0.04 0.002 1.71 0.99, 2.97 0.05 
Multivariable-adjusted 
Model 3f 
 
2.23 1.28, 3.87 0.004 0.13 0.04 0.005 1.61 0.90, 2.87 0.11 
Multivariable-adjusted 
Model 4g 
 
2.07 1.21, 3.55 0.008 0.11 0.04 0.01 1.55 0.87, 2.75 0.13 
Long-term perceived 
weight 
discriminationc,h 
         
Age- and sex-adjusted 
 
2.50 1.72, 3.63 <0.0001 0.21 0.04 <0.0001 1.87 1.25, 2.79 0.002 
Multivariable-adjusted 
Model 1d 
 
2.47 1.65, 3.69 <0.0001 0.21 0.04 <0.0001 1.79 1.15, 2.78 0.01 
Multivariable-adjusted 
Model 2e 
 
2.37 1.58, 3.56 <0.0001 0.20 0.04 <0.0001 1.73 1.11, 2.69 0.02 
Multivariable-adjusted 
Model 3f 
 
2.27 1.45, 3.56 0.0003 0.21 0.05 <0.0001 1.66 1.03, 2.69 0.04 
Multivariable-adjusted 
Model 4g 
 
2.16 1.39, 3.36 0.0007 0.19 0.05 0.0001 1.62 1.01, 2.62 0.047 
aHigh allostatic load was defined as greater than or equal to 3 dysregulated systems, and low allostatic load was defined as less 622 
than 3.  Allostatic load was measured at follow-up, and medication usage was included in the definition. 623 
bFamily status was added to the continuous models as a random effect.  624 
cOnly individuals who reported discrimination “sometimes” or “often” were coded as having experienced discrimination. 625 
dModel 1 includes age, sex, race (white, black, other), household income (>$100,000/year), smoking status (never, former, 626 
current), educational attainment (< high school, high school graduate, some college, college graduate or more) 627 
eModel 2 includes covariates in Model 1 plus engagement in regular exercise at least 20 min 3 times per week 628 
fModel 3 includes covariates in Models 1-2 plus perceived race, sex, and age discrimination at baseline 629 
gModel 4 includes covariates in Models 1-3 plus baseline BMI 630 
hLong-term weight discrimination was computed as the average value of perceived discrimination at baseline and at 10-year 631 
follow-up for those who had both measures.  For individuals with no baseline measure, but with a measure at 10-years, long-term 632 
discrimination was computed as their reported discrimination at 10-years. 633 
 634 
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Table 4: Relative Risk of High Allostatic Load System Parameters based on Perceived Long-Term Weight 635 
Discrimination in the MIDUS Studya 636 
 Percent with 
dysregulated 
system 
RR 95% CI p-value 
     
Cardiovascular 38.6    
Age and sex-adjusted 
 
 1.37 1.03, 1.81 0.03 
Model1b 
 
 1.26 0.92, 1.72 0.15 
Model 2c 
 
 1.20 0.89, 1.65 0.23 
Model 3d 
 
 1.24 0.89, 1.72 0.20 
Model 4e 
 
 1.23 0.89, 1.72 0.21 
Metabolic 18.3    
Age and sex-adjusted 
 
 2.07 1.49, 2.88 <0.0001 
Model 1b 
 
 2.07 1.45, 2.97 <0.0001 
Model 2c 
 
 1.96 1.35, 2.82 0.0003 
Model 3d 
 
 1.66 1.07, 2.57 0.02 
Model 4e 
 
 1.56 1.02, 2.40 0.04 
Glucose Metabolism 23.5    
Age and sex-adjusted 
 
 2.29 1.62, 3.24 <0.0001 
Model 1b 
 
 2.29 1.43, 3.67 0.0006 
 Model 2c 
 
 2.26 1.59, 3.22 <0.0001 
Model 3d 
 
 2.10 1.40, 3.15 0.0003 
Model 4e  1.99 1.34, 2.95 0.0006 
Inflammation 26.6    
Age and sex-adjusted 
 
 1.89 1.37, 2.61 <0.0001 
Model 1b 
 
 1.99 1.44, 2.76 <0.0001 
Model 2c 
 
 1.91 1.37, 2.67 0.0001 
Model 3d  1.83 1.27, 2.64 0.001 
Model 4e 
 
 1.76 1.22, 2.54 0.003 
Sympathetic Nervous Systemf 12.4    
Age and sex-adjusted 
 
 1.27 0.70, 2.32 0.43 
Model 1b 
 
 1.26 0.67, 2.35 0.47 
Model 2c  1.24 0.66, 2.32 0.50 
30 
 
 
Model 3d 
 
 1.31 0.64, 2.68 0.46 
Model 4e 
 
 1.44 0.70, 2.96 0.32 
Hypothalamic Pituitary Axis 43.6    
Age and sex-adjusted 
 
 0.94 0.71, 1.24 0.66 
Model 1b 
 
 0.96 0.71, 1.28 0.77 
Model 2c 
 
 0.97 0.72, 1.30 0.84 
Model 3d 
 
 0.94 0.69, 1.30 0.72 
Model 4e 
 
 0.95 0.69, 1.31 0.77 
Parasympathetic Nervous 
Systemf 
19.6    
Age and sex-adjusted 
 
 1.42 0.90, 2.23 0.13 
Model 1b 
 
 1.42 0.86, 2.33 0.17 
 Model 2c 
 
 1.38 0.83, 2.29 0.21 
Model 3d 
 
 1.28 0.75, 2.21 0.36 
Model 4e 
 
 1.29 0.75, 2.21 0.37 
 637 
aLong-term perceived weight discrimination represents the average value of perceived discrimination at baseline and at 638 
follow-up for those who had both measures.  For individuals with only one measure, long-term discrimination represents 639 
their reported discrimination at that time point 640 
bModel 1 includes age, sex, race (white, black, other), household income (>$100,000/year), smoking status (never, former, 641 
current), educational attainment (< high school, high school graduate, some college, college graduate or more) 642 
cModel 2 includes covariates in Model 1 plus engagement in regular exercise at least 20 min 3 times per week 643 
dModel 3 includes covariates in Models 1-2 plus perceived race, sex, and age discrimination at baseline 644 
eModel 4 includes covariates in Models 1-3 plus baseline BMI 645 
fMedication usage was not considered in the diagnosis of Parasympathetic Nervous System or Sympathetic Nervous System 646 
dysregulation. 647 
 648 
